Zydus Cadila has received final approval from The US Food and Drug Administration (USFDA) to market Ezetimibe Tablets USP, 10 mg. Ezetimibe is a drug used to reduce high cholesterol levels. It will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The estimated sales for Ezetimibe Tablets is $2.7 billion, as per IMS MAT April 2017.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
